National Bank of Canada
PBYI icon

National Bank of Canada’s Puma Biotechnology PBYI Stock Holding History

National Bank of Canada’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10
Closed -$59 – 3149
2025
Q4 		$59 Buy
+10
New +$53 ﹤0.01% 2809

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

National Bank of Canada's PBYI Position: Q1 2026 in Review

National Bank of Canada sold out of Puma Biotechnology (PBYI) in Q1 2026, closing a stake of 10 shares — an estimated $59 sold.

National Bank of Canada first reported a position in PBYI in Q4 2025 and held it in 1 quarter. The position peaked at $59 in Q4 2025. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • National Bank of Canada reported no remaining Puma Biotechnology position as of Q1 2026 after selling out during the quarter.
  • National Bank of Canada sold 10 Puma Biotechnology shares in Q1 2026, an estimated $59.
  • National Bank of Canada first reported a position in Puma Biotechnology in Q4 2025 and held it in 1 quarter.
  • National Bank of Canada's Puma Biotechnology position peaked at $59 in Q4 2025.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.